BMS files Opdivo in post-surgery setting
Opdivo performed better than BMS’ Yervoy in clinical trial.
X
BMS files Opdivo in post-surgery setting
https://pharmaphorum.com/news/bms-looks-licence-opdivo-suppress-melanoma-surgery/
melanoma
Immunocore hires Lilly’s Hotchkiss as chief commercial officer
UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
NICE rejects Roche’s skin cancer combo
Novartis’ rival combination better value, says NICE.
NICE recommends Amgen’s melanoma treatment after price cut
Drug only approved when systemic immunotherapies are not suitable
Imbruvica, Opdivo and Praluent gain approvals for Scotland’s NHS
Sanofi steals a march on rivals Amgen
Digital health round-up – skin cancer, vocal biomarkers and more
A round-up of this week’s top digital healthcare news. Marco Ricci reports.
Inaugural UK melanoma patient conference bridges doctor-patient gap
A total of 250 delegates including experts in the field and patients attended the event.
NICE recommends BMS melanoma combination
NICE makes swift decision on skin cancer treatment.
